Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Increased Functional T Cell Defects in Patients with low CD4 Counts after Allogeneic Hematopoietic Stem Cell Transplantation

Udo Holtick, MD PhD, Lukas P. Frenzel, MD, Shimabukuro-Vornhagen Alexander, MD, Sebastian Theurich, MD, Julia Claasen, Christof Scheid, MD, PhD, Michael von-Bergwelt-Baildon, MD PhD, Michael Hallek, MD PhD, Clemens Wendtner, MD, Jens M. Chemnitz, MD

Blood (2013) 122 (21): 4588.

https://doi.org/10.1182/blood.V122.21.4588.4588

Published: 2013

Journal Articles

The Use of Chemoimmunotherapy Improves the Outcome of Patients with Chronic Lymphocytic Leukaemia (CLL) – a Metaanalysis of Five Trials of the German CLL Study Group (GCLLSG)

Paula Cramer, MD, Susanne Isfort, MD, Jasmin Bahlo, Raymonde Busch, Petra Langerbeins, MD, Anna-Maria Fink, MD, Valentin Goede, MD, Thomas Elter, MD, Manuela A. Bergmann, MD, Martina Beate Stauch, MD, Stephan Stilgenbauer, MD, Clemens-Martin Wendtner, MD, Kirsten Fischer, MD, Michael Hallek, MD PhD, Barbara F. Eichhorst, MD

Blood (2012) 120 (21): 3936.

https://doi.org/10.1182/blood.V120.21.3936.3936

Published: 2012

Journal Articles

CD30-Targeted Therapy with Brentuximab Vedotin Combined with Donor Lymphocyte Infusions Induce Sustained Clinical Remissions and Tumor Specific Immunity in a Series of Patients with Relapsed Hodgkin Lymphoma After Allogeneic Stem Cell Transplantation

Sebastian Theurich, MD, Joke Malcher, Kerstin Wennhold, Alexander Shimabukuro-Vornhagen, MD, Jens M. Chemnitz, MD, Holtick Udo, MD, Anke Krause, MD, Carsten Kobe, MD, Deniz Kahraman, MD, Chakupurakal Geothy, Andreas Engert, MD PhD, Scheid Christof, MD, Michael Hallek, MD PhD, Michael von Bergwelt-Baildon, MD, PhD

Blood (2012) 120 (21): 4213.

https://doi.org/10.1182/blood.V120.21.4213.4213

Published: 2012

Journal Articles

Quantitative MRD Assessments Predict Progression Free Survival in CLL Patients Treated with Fludarabine and Cyclophosphamide with or without Rituximab – a Prospective Analysis in 471 Patients from the Randomized GCLLSG CLL8 Trial

Sebastian Boettcher, MD, Kirsten Fischer, MD, Stephan Stilgenbauer, MD, PhD, Raymonde Busch, Günter Fingerle-Rowson, MD, PhD, Anna-Maria Fink, MD, Hartmut Döhner, MD, PhD, Michael Hallek, MD, PhD, Michael Kneba, MD, PhD, Matthias Ritgen, MD, on Behalf Of GCLLSG

Blood (2008) 112 (11): 326.

https://doi.org/10.1182/blood.V112.11.326.326

Published: 2008

Journal Articles

Standardized MRD Flow and ASO IGH RQ-PCR for MRD Quantification in CLL Patients after Rituximab-Containing Immunochemotherapy – a Comparative Analysis in 574 Samples from the Randomized GCLLSG CLL8 Trial

Sebastian Boettcher, MD, Stephan Stilgenbauer, MD, PhD, Raymonde Busch, Monika Brüggemann, MD, PhD, Thorsten Raff, MD, Kirsten Fischer, MD, Günter Fingerle-Rowson, MD, PhD, Anna-Maria Fink, MD, Christiane Pott, MD, Hartmut Döhner, MD, PhD, Michael Hallek, MD, PhD, Michael Kneba, MD, PhD, Matthias Ritgen, MD, on Behalf Of GCLLSG

Blood (2008) 112 (11): 3139.

https://doi.org/10.1182/blood.V112.11.3139.3139

Published: 2008

Journal Articles

Rituximab Is the Essential Treatment Modality That Underlies the Significant Improvement in Short and Long Term Outcome of Patients with Advanced Stage Follicular Lymphoma - A 10 Year Analysis of GLSG Trials.

Wolfgang Hiddemann, MD, PhD, Eva Hoster, MSc, Christian Buske, MD, PhD, Martin Dreyling, MD, PhD, Michael Kneba, MD, PhD, Michael Hallek, MD, PhD, Eva Lengfelder, MD, Hannes Wandt, MD, PhD, Michael Unterhalt, MD

Blood (2006) 108 (11): 483.

https://doi.org/10.1182/blood.V108.11.483.483

Published: 2006

Journal Articles

Coculture of Pediatric Acute Lymphoblastic Leukemia (ALL) Blasts with CD40 Ligand Transfected Cells Leads to Changes of Surface Antigens and RNA Expression.

Daniel K. Stachel, MD, Uta Eickelmann, MD, Rita Meilbeck, M.T., Michael H. Albert, MD, Raymund Buhmann, MD, Michael Hallek, MD, PhD, Irene Schmid, MD

Blood (2005) 106 (11): 856.

https://doi.org/10.1182/blood.V106.11.856.856

Published: 2005

Journal Articles

PEG-Interferon for Chronic Phase CML - Still an Option in the Era of Imatinib?.

Christof Scheid, MD, Andreas Draube, MD, Udo Holtick, MD, Oliver Cornely, MD, Ulrich Hacker, MD, Michael Fuchs, MD, Ute Berger, MD, Andreas Hochhaus, MD, PhD, Rüdiger Hehlmann, MD, PhD, Michael Hallek, MD, PhD

Blood (2004) 104 (11): 4662.

https://doi.org/10.1182/blood.V104.11.4662.4662

Published: 2004

NARROW

Increased Functional T Cell Defects in Patients with low CD4 Counts after Allogeneic Hematopoietic Stem Cell Transplantation

The Use of Chemoimmunotherapy Improves the Outcome of Patients with Chronic Lymphocytic Leukaemia (CLL) – a Metaanalysis of Five Trials of the German CLL Study Group (GCLLSG)

CD30-Targeted Therapy with Brentuximab Vedotin Combined with Donor Lymphocyte Infusions Induce Sustained Clinical Remissions and Tumor Specific Immunity in a Series of Patients with Relapsed Hodgkin Lymphoma After Allogeneic Stem Cell Transplantation

Quantitative MRD Assessments Predict Progression Free Survival in CLL Patients Treated with Fludarabine and Cyclophosphamide with or without Rituximab – a Prospective Analysis in 471 Patients from the Randomized GCLLSG CLL8 Trial

Standardized MRD Flow and ASO IGH RQ-PCR for MRD Quantification in CLL Patients after Rituximab-Containing Immunochemotherapy – a Comparative Analysis in 574 Samples from the Randomized GCLLSG CLL8 Trial

Rituximab Is the Essential Treatment Modality That Underlies the Significant Improvement in Short and Long Term Outcome of Patients with Advanced Stage Follicular Lymphoma - A 10 Year Analysis of GLSG Trials.

Coculture of Pediatric Acute Lymphoblastic Leukemia (ALL) Blasts with CD40 Ligand Transfected Cells Leads to Changes of Surface Antigens and RNA Expression.

PEG-Interferon for Chronic Phase CML - Still an Option in the Era of Imatinib?.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only